Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

‘Rapid Adoption’ Expected For US Humira Biosimilars

AmerisourceBergen’s McGowan Also Sees Oncology Biosimilars Capturing Record Market Share

Executive Summary

Uptake is expected to be “rapid” once Humira biosimilars launch in the US, according to Sean McGowan, senior director of biosimilars at AmerisourceBergen. Meanwhile, milestone first approvals for interchangeable and ophthalmic biosimilars show that the US biosimilars market is moving in the right direction, he tells Generics Bulletin in an exclusive Q&A.

You may also be interested in...



Cigna: US Adalimumab Prices Could Vary Meaningfully

Cigna has responded to several questions from the insurer/payer side on the potential effect of multiple biosimilar Humira products launching in 2023 and beyond.

Humira One Year Out: The Largest LOE Event In US Pharma History

Ahead of the first biosimilar Humira product set to launch in less than a year, In Vivo provides a comprehensive run-down of where biosimilar sponsors stand and the key issues ahead of market formation.

Biosimilars To Generate $215bn In Savings Through 2026, Says IQVIA

Biosimilar competition, spurred on by significant losses of exclusivity for major products like Humira, Stelara and Xarelto, will lead to significant cost savings for healthcare systems and patients over the next five years according to a recent report from IQVIA. While these entrants are set to limit growth in the branded pharmaceuticals space, innovation is set to continue driving global spending.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

GB151458

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel